Expressing Recombinant Antigen Patents (Class 435/362)
  • Patent number: 6066503
    Abstract: The present invention provides nucleic acid molecules containing nucleotide sequences encoding helminth aminopeptidase enzymes, and antigenic fragments and functionally-equivalent variants thereof, their use in the preparation of vaccines for use against helminth parasites, and synthetic polypeptides encoded by them.
    Type: Grant
    Filed: January 9, 1995
    Date of Patent: May 23, 2000
    Assignee: Barbraham Institute
    Inventors: Margaret Graham, Trevor Stanley Smith, Edward Albert Munn, David Patrick Knox, Joanna Jane Oliver, Susan Elizabeth Newton
  • Patent number: 6051426
    Abstract: The invention concerns a composition useful for the manufacture of vaccines containing particles having the immunogenic properties characteristic of the antigen HBsAg, these particles being more particularly characterized by the fact that the particles equally contain a receptor for polymerized human albumin. They are obtained by transformation of human or animal cells by a vector containing a DNA sequence coding for the S and pre-S regions of a genome of viral hepatitis B, this DNA sequence being placed under the direct control of a promoter permitting the effective transcription of the sequence in the human or animal cells transformable by the vector.
    Type: Grant
    Filed: February 6, 1995
    Date of Patent: April 18, 2000
    Assignee: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale and Centre National de la Recherche Scientifique
    Inventors: Elaine Sobczak, Yves Malpiece, deceased, Marie-Louise Michel, Pierre Tiollais, Rolf E. Streeck
  • Patent number: 6043085
    Abstract: The present invention provides a 120-kDa protein gene of Ehrlichia canis, amplified by PCR using primers derived from the DNA sequences flanking the Ehrlichia chaffeensis 120-kDa protein gene. The recombinant E. canis 120-kDa protein contains 14 tandem repeat units with 36 amino acids each. The repeat units are hydrophilic and predicted to be surface-exposed. Also disclosed is that the recombinant E. canis 120-kDa protein is antigenic and reacts with sera from dogs convalescent from canine ehrlichiosis.
    Type: Grant
    Filed: August 27, 1998
    Date of Patent: March 28, 2000
    Assignee: Research Development Foundation
    Inventors: Xue-Jie Yu, David H. Walker
  • Patent number: 6030638
    Abstract: A novel plasmid has inserted therein the cDNA for prostaglandin synthase. The present invention further provides a method of increasing prostanoid production in vivo including the general steps of delivering a prostaglandin synthase gene to cells in vivo and hyperexpressing the gene to enhance prostanoid production in the cells.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 29, 2000
    Assignee: Vanderbilt University
    Inventors: Kenneth Brigham, Jon T. Conary, Angelo Canonico, Barbara Meyrick
  • Patent number: 6025162
    Abstract: A substantially pure, covalently linked human T cell reactive feline protein (TRFP) has been isolated from vacuum bag extract obtained by affinity purification of house dust collected from several homes with cats; DNA encoding all or a portion of the TRFP or peptide; compositions containing such a protein or peptide or portions thereof; and antibodies reactive with the TRFP or peptide are disclosed. Also disclosed are recombinant TRFP or peptide; modified or mutated TRFP peptides; their use for diagnostic or therapeutic purposes.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: February 15, 2000
    Assignee: Immulogic Pharmaceutical Corporation
    Inventors: Bruce L. Rogers, Irwin J. Griffith, Jay P. Morgenstern
  • Patent number: 5935818
    Abstract: This invention provides an isolated mammalian nucleic acid molecule encoding an alternatively spliced prostate-specific membrane (PSM') antigen. This invention provides an isolated nucleic acid molecule encoding a prostate-specific membrane antigen promoter. This invention provides a method of detecting hematogenous micrometastic tumor cells of a subject, and determining prostate cancer progression in a subject.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: August 10, 1999
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Ron S. Israeli, Warren D. W. Heston, William R. Fair
  • Patent number: 5928898
    Abstract: The invention provides isolated nucleic acid compounds encoding a multiple drug resistance protein of Aspergillus nidulans. Vectors and transformed host cells comprising the multiple drug resistance-encoding DNA of Aspergillus nidulans atrD are also provided. The invention further provides assays which utilize these transformed host cells.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: July 27, 1999
    Assignee: Eli Lilly and Company
    Inventors: Paul Luther Skatrud, Maarten A. de Waard, Alan C. Andrade, Robert Brown Peery
  • Patent number: 5888770
    Abstract: The invention provides spoIIIE polypeptides and DNA (RNA) encodig spoIIIE polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utlizng spoIIIE polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: August 26, 1997
    Date of Patent: March 30, 1999
    Assignee: Smithkline Beecham Corporation
    Inventors: Alison Frances Chalker, Maria Magdalena Zalacain Feliu, James Raymond Brown, Alexander Philip Bryant
  • Patent number: 5885805
    Abstract: The invention provides gbpA polypeptides and DNA (RNA) encoding gbpA polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing gbpA polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: August 20, 1997
    Date of Patent: March 23, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Michael Arthur Lonetto, Patrick Vernon Warren, Michael Terence Black, John Edward Hodgson, David Justin Charles Knowles, Raymond Winfield Reichard, Richard Oakley Nicholas, Martin Karl Russel Burnham, Julie M Pratt, Martin Rosenberg, Judith M Ward
  • Patent number: 5882898
    Abstract: The invention provides folC polypeptides and DNA (RNA) encoding folC polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing folC polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: March 16, 1999
    Assignees: Smithkline Beecham Corporation, Smithkline Beecham p.l.c.
    Inventors: Stewart Campbell Pearson, Rebecca Claire Greenwood
  • Patent number: 5882896
    Abstract: The invention provides M Protein polypeptides and DNA (RNA) encoding M Protein polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing M Protein polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: September 15, 1997
    Date of Patent: March 16, 1999
    Assignees: Smithkline Beecham Corporation, Smithkline Beecham, p.l.c.
    Inventors: Martin Karl Russel Burnham, Stephen Dudley Holmes
  • Patent number: 5876722
    Abstract: The invention provides a DNA encoding at least one part of genetic information of protein which has biochemical and immunological properties of a major allergen of Dermatophagoides farinae (Derf II).
    Type: Grant
    Filed: August 12, 1997
    Date of Patent: March 2, 1999
    Assignees: Asahi Breweries, Ltd., Torii & Co., Ltd.
    Inventors: Toshifumi Yuuki, Yasushi Okumura, Hiroshi Yamakawa
  • Patent number: 5877017
    Abstract: A family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as BAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as BAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.
    Type: Grant
    Filed: February 16, 1995
    Date of Patent: March 2, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascale Boel, Claude Wildmann, Thierry Boon-Falleur, Pierre van der Bruggen, Pierre Coulie, Jean-Christophe Renauld
  • Patent number: 5874251
    Abstract: Antigens derived from Taenia crassiceps have been isolated which have specificity and sensitivity in their reactivity with antibodies against Taenia saginata and Taenia solium. These antigens may therefor be used in diagnostic testing for the serological screening of livestock for cysticercosis, rather than relying upon methods involving dissection and visual examination.
    Type: Grant
    Filed: May 15, 1996
    Date of Patent: February 23, 1999
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Dante Sam Zarlenga, Jr., Marcia Louise Rhoads
  • Patent number: 5874300
    Abstract: The present invention provides an isolated nucleic acid encoding an approximately 26 kilodalton antigen, PEB1A, of Campylobacter jejuni, or an antigenic fragment thereof, wherein the antigen is associated with diarrheal disease. The present invention also provides methods of detecting the presence of a Campylobacter jejuni strain possessing the PEB1A antigen in a subject. Vaccines and treatments for C. jejuni infection are provided, as is a mutant C. jejuni not expressing a functional PEB1A antigen.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: February 23, 1999
    Assignee: Enteric Research Laboratories
    Inventors: Martin J. Blaser, Zhiheng Pei
  • Patent number: 5874250
    Abstract: The present invention relates to a protein containing the extracellular domain of LAG-3, and DNA sequences coding for the protein and the pharmaceutical and biological uses of the protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: February 23, 1999
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Gustave Roussy
    Inventors: Thierry Hercend, Frederic Triebel
  • Patent number: 5834245
    Abstract: A gene is provided which is present in the deletion region of a chromosome common in lung cancer, hepatocellular carcinoma and colorectal cancer and encodes a novel protein, a protein encoded by the gene (PRLTS protein), and a method of discriminating tumor cells. With respect to the human chromosome 8, a detailed gene map was prepared, the chromosome of each of lung cancer, hepatocellular carcinoma and colorectal cancer tissues was analyzed, and a gene encoding a novel protein was cloned to thereby determine the structure thereof. A gene analysis was conducted with the use of a DNA probe derived from the above gene, and consequently mutations in the gene were confirmed in the lung cancer, hepatocellular carcinoma and colorectal cancer tissues.
    Type: Grant
    Filed: July 25, 1995
    Date of Patent: November 10, 1998
    Assignees: Cancer Institute, Eisai Co., Ltd.
    Inventors: Yusuke Nakamura, Yoshiyuki Fujiwara
  • Patent number: 5786176
    Abstract: The invention relates to recombinant cell lines, in particular mamalian cell lines, capable of expressing recombinant CDw52 antigen or an antigenic fragment thereof. The cell lines can be used for the production of recombinant CDw52 antigen and in assaying for anti-CDw52 antibody in a sample.
    Type: Grant
    Filed: February 3, 1995
    Date of Patent: July 28, 1998
    Assignee: British Technology Group Limited
    Inventors: Geoffrey Hale, Herman Waldmann, Masahide Tone, John Tite, Christine Hale
  • Patent number: 5773253
    Abstract: The invention provides CTLA4 mutant molecules as ligands for the B7 antigen. Methods are provided for expressing CTLA4 mutant molecules as soluble, functional molecules, for preparing CTLA4 mutant fusion proteins, and for using these soluble molecules to regulate T cell interactions and immune responses mediated by such interactions.
    Type: Grant
    Filed: July 21, 1995
    Date of Patent: June 30, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: Peter S. Linsley, Jeffrey A. Ledbetter, Robert Peach
  • Patent number: 5674709
    Abstract: The present invention provides recombinant DNA molecules comprising a sequence encoding a pseudorabies virus (PRV) glycoprotein selected from the group consisting of gI, gp50, and gp63, host cells transformed by said recombinant DNA molecule sequences, the gI, gp50 and gp63 polypeptides. The present invention also provides subunit vaccines for PRY, methods for protecting animals against PRV infection and methods for distinguishing between infected and vaccinated animals.
    Type: Grant
    Filed: June 21, 1994
    Date of Patent: October 7, 1997
    Assignee: Pharmacia & Upjohn Company
    Inventors: Erik Aivars Petrovskis, Leonard Edwin Post, James G. Timmins
  • Patent number: 5665577
    Abstract: Packaging defective and packaging proficient HIV vectors are disclosed. These vectors can be used to establish HIV packaging defective cell lines, and to package desired genes. These cell lines can be used in developing a vaccine, HIV antibodies and as part of a system for gene transfer. The packaging proficient vector can be used to target HIV target cells.
    Type: Grant
    Filed: November 15, 1993
    Date of Patent: September 9, 1997
    Assignee: Dana-Farber Cancer Institute
    Inventors: Joseph G. Sodroski, William A. Haseltine, Mark Poznansky, Andrew Lever, Heinrich Gottlinger
  • Patent number: 5665592
    Abstract: Disclosed is an isolated and purified feline immunodeficiency virus (FIV) culture having the identifying characteristics of FIV isolate NCSU.sub.1. A biologically pure culture of host cells containing a FIV having the identifying characteristics of FIV isolate NCSU.sub.1 is also disclosed, along with isolated and purified DNA coding for (a) an FIV having the identifying characteristics of FIV isolate NCSU.sub.1, or (b) an antigenic fragment of an FIV having the identifying characteristics of FIV isolate NCSU.sub.1. Various vaccine formulations containing active agents derived from the foregoing FIV virus, DNA encoding the virus, and DNA encoding antigenic fragments of the virus are also disclosed herein.Also disclosed are immunodeficient mice containing feline tissue, which feline tissue is capable of infection with a feline immunodeficiency virus such as (but not limited to) FIV isolate NCSU.sub.1.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: September 9, 1997
    Assignee: North Carolina State University
    Inventors: Wayne A. F. Tompkins, Mary B. Tompkins
  • Patent number: 5663315
    Abstract: The invention features a method for diagnosis of pancreatitis by detecting an elevation in the amount of GP2 pancreatic glycoprotein in a sample of bodily fluid such as human blood, serum, or urine. The invention also features isolated DNA encoding human GP2, a method for producing recombinant human GP2, antibodies which specifically bind to human GP2, a method for producing anti-human GP2 antibodies, and a kit for use in the diagnosis of pancreatitis.
    Type: Grant
    Filed: December 6, 1994
    Date of Patent: September 2, 1997
    Assignee: AlphaGene, Inc.
    Inventors: George Scheele, Shin-Ichi Fukuoka
  • Patent number: 5646009
    Abstract: A hybrid vector carrying a first and second DNA segments operationally linked thereto, the first DNA segment encoding a protein capable of cross-linking to the cap structure of mRNA and mediating ribosome-binding, and the second DNA segment encoding a polypeptide or protein, the vector being capable of replication, transcription and translation to express the factor and the polypeptide or protein upon transformation of a eukaryotic host, and the polypeptide or protein being expressed at a level higher than the level of expression thereof in the absence of the first DNA segment. A eukaryotic host is transformed with this hybrid vector. Also disclosed is a method of increasing the synthesis of a polypeptide or protein in a eukaryotic host cell.
    Type: Grant
    Filed: January 19, 1994
    Date of Patent: July 8, 1997
    Assignee: The University of Kentucky Research Foundation
    Inventors: Robert E. Rhoads, Arrico De Benedetti
  • Patent number: 5624827
    Abstract: The present invention provides the nucleotide sequence for a synthetic gene for the plant toxin gelonin and a process for producing, cloning and expressing this synthetic gene. The DNA sequence for a synthetic gene for gelonin as shown in sequence ID NO. 1. The present invention also provides expression vectors containing the DNA sequences for gelonin and cells transformed with these vectors. In addition, an immunotoxin comprising an antibody of conjugated to the protein gelonin.
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: April 29, 1997
    Assignee: Research Development Foundation
    Inventors: Michael G. Rosenblum, Kenneth L. Beattie
  • Patent number: 5610013
    Abstract: A new family of tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as GAGE tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as GAGE coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigens, and their precursor molecules are described.
    Type: Grant
    Filed: May 27, 1994
    Date of Patent: March 11, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Benoit Van den Eynde, Thierry Boon-Falleur